February 8, 2017
OptiBiotix to trade new shares on AIM (London)
OptiBiotix Health has been notified by from warrant holders to exercise warrants over 16,351 ordinary shares
Pharmaceuticals, Biotechnology and Life Sciences
Category: Regions
February 8, 2017
Sanofi’s 2016 income slightly down
Sanofi has reported net income of €1,6 billion for Q4 2016 which is 6% down compared to the same period last year. The full year income was €7.3 billion, 0.9% down from the last year.
February 8, 2017
Zealand gets $3.3M from Sanofi’s sales of Lyxumia
Zealand Pharma has reported royalty revenue from Sanofi’s sales of Lyxumia (lixisenatide) outside the United States of €0.7 million for Q4 2016 and annual royalty revenue of €3.3 million in 2016.
February 7, 2017
Teva appoints Dr. Yitzhak Peterburg as interim CEO, Erez Vigodman steps down
Teva ‘s chief executive officer Erez Vigodman has stepped down from its position, and the Israel’s largest drugmaker has appointed Dr. Yitzhak Peterburg, who has served as Chairman of the Teva’s Board since January 2015, as Interim President CEO.
February 7, 2017
Nanobiotix’s finds new COO in ex Novartis Germany Oncology GM
Nanobiotix has appointmented Alain Dostie, a senior executive from the pharmaceutical industry, as its Chief Operating Officer (COO).
February 7, 2017
Amryt secures Japanese patent for its “butterfly children” drug candidate Episalvan, soon kicks off phase III study
Amryt has secured a patent in Japan for its skin disorder drug candidate Episalvan, and it is waiting to kick off the third phase clinical trial by the end of March 2017.
February 7, 2017
FDA gives Cellectis IND approval to start clinical trial for AML and BPDCN drug
U.S. Food and Drug Administration (FDA) has granted a French based biopharmaceutical company Cellectis an Investigational New Drug (IND) approval to start first phase clinical trial with UCART123 in patients with acute myeloid leukemia (AML) and blastic plasmacytoid dendritic cell neoplasm (BPDCN)
February 6, 2017
Advanced Oncotherapy exits deal with Sinophi for its China&SE Asia proton therapy system
Advanced Oncotherapy has dropped taking legal measures against Sinophi Healthcare Limited (Sinophi), as the companies have agreed to terminate the purchase from March and October 2015.
February 6, 2017
Kiadis Pharma in phase 3 with leukemia drug ATIR101
Kiadis Pharma has started its phase III trial with its major products for blood cancer hematopoietic stem cell transplantation (HSCT) ATIR101.
February 6, 2017
Innate Pharma’s acute myeloid leukemia drug testing disappoints
Innate Pharma’s “EffiKIR” trial of lirilumab as a single agent maintenance treatment in elderly patients with acute myeloid leukemia (AML) in first complete remission, did not meet its primary efficacy endpoint of leukemia-free survival (LFS).